140 related articles for article (PubMed ID: 11711285)
1. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
Maltais R; Luu-The V; Poirier D
Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and optimization of a new family of type 3 17 beta-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry.
Maltais R; Luu-The V; Poirier D
J Med Chem; 2002 Jan; 45(3):640-53. PubMed ID: 11806715
[TBL] [Abstract][Full Text] [Related]
3. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
4. Androsterone derivatives substituted at position 16: chemical synthesis, inhibition of type 3 17beta-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells.
Tchédam-Ngatcha B; Luu-The V; Poirier D
J Enzyme Inhib Med Chem; 2002 Jun; 17(3):155-65. PubMed ID: 12443041
[TBL] [Abstract][Full Text] [Related]
5. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
[TBL] [Abstract][Full Text] [Related]
6. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
7. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
Bérubé M; Laplante Y; Poirier D
Med Chem; 2006 Jul; 2(4):329-47. PubMed ID: 16848745
[TBL] [Abstract][Full Text] [Related]
9. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
10. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
11. N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity.
Sam K; Labrie F; Poirier D
Eur J Med Chem; 2000 Feb; 35(2):217-25. PubMed ID: 10758283
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Bellavance E; Luu-The V; Poirier D
J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
[TBL] [Abstract][Full Text] [Related]
14. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3.
Provost PR; Blomquist CH; Godin C; Huang XF; Flamand N; Luu-The V; Nadeau D; Tremblay Y
Endocrinology; 2000 Aug; 141(8):2786-94. PubMed ID: 10919264
[TBL] [Abstract][Full Text] [Related]
15. The altered specificity of cortisone reductase with certain retroandrostan-3-one substrates.
Gibb W; Jeffery J
Biochem J; 1975 Mar; 145(3):483-9. PubMed ID: 168869
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
[TBL] [Abstract][Full Text] [Related]
17. Pathways and genes involved in steroid hormone metabolism in male pigs: a review and update.
Robic A; Faraut T; Prunier A
J Steroid Biochem Mol Biol; 2014 Mar; 140():44-55. PubMed ID: 24239507
[TBL] [Abstract][Full Text] [Related]
18. Assessment of steroidogenesis and steroidogenic enzyme functions.
Luu-The V
J Steroid Biochem Mol Biol; 2013 Sep; 137():176-82. PubMed ID: 23770321
[TBL] [Abstract][Full Text] [Related]
19. Sebocytes are the key regulators of androgen homeostasis in human skin.
Fritsch M; Orfanos CE; Zouboulis CC
J Invest Dermatol; 2001 May; 116(5):793-800. PubMed ID: 11348472
[TBL] [Abstract][Full Text] [Related]
20. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
